SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 30, 2002; DOI 10.1182/blood-2002-02-0408. This Article Full Text (PDF) All Versions of this Article: 2002-02-0408v1 100/3/961    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chiriva-Internati, M. Articles by Lim, S. H Search for Related Content PubMed PubMed Citation Articles by Chiriva-Internati, M. Articles by Lim, S. H Social Bookmarking                   What's this? Submitted February 8, 2002 Accepted March 12, 2002 Sperm protein 17 (Sp17)is a suitable target for immunotherapy of multiple myeloma Maurizio Chiriva-Internati, Zhiqing Wang, Emanuela Salati, Klaus Bumm, Bart Barlogie, and Seah H Lim* Blood Stem Cell Transplantation Program, Harrington Cancer Center, Amarillo, Texas, USA; Division of Hematology and Oncology, Texas Tech University Health Sciences Center, Amarillo, Texas, USA Division of Hematology and Oncology, Texas Tech University Health Sciences Center, Amarillo, Texas, USA Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA * Corresponding author; email: slim{at}harringtoncc.org. Sperm protein 17 (Sp17) is a protein recently identified as a novel cancer-testis (CT) antigen in multiple myeloma (MM). Since this tumor antigen demonstrates a very restricted normal tissue expression, Sp17 may be an excellent target for tumor vaccine of MM. In this present study, we determined the ability to generate Sp17-specific HLA-class I restricted CTLs from the peripheral blood of 4 patients with MM, 3 consecutive Sp17-positive patients and one Sp17-negative patient. Dendritic cells were generated from monocytes of four patients with MM and used to present a recombinant Sp17 protein to autologous T cells. Following four rounds of antigen stimulation, the CTLs were tested for their ability to kill autologous targets in an Sp17 dependent and HLA-class I restricted manner in standard cytotoxicity assays. Despite previous chemotherapy and the immunosuppression so often associated with multiple myeloma, CTL generation was successful in all 4 patients, irrespectively of the Sp17 status of their tumors. Most importantly, the CTLs were able to lyse autologous tumor cells that expressed Sp17. Tumor cell lysis in all cases appeared to be mainly perforin-mediated and could be blocked by Concanamycin A. We conclude that Sp17 is a suitable target for immunotherapy of multiple myeloma. Our findings provide the basis for a clinical study aimed at inducing a cellular immune response directed at Sp17-positive MM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. J. Chng, S. Kumar, S. VanWier, G. Ahmann, T. Price-Troska, K. Henderson, T.-H. Chung, S. Kim, G. Mulligan, B. Bryant, et al. Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling Cancer Res., April 1, 2007; 67(7): 2982 - 2989. [Abstract] [Full Text] [PDF] M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al. Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis J. Immunol., March 1, 2007; 178(5): 3307 - 3315. [Abstract] [Full Text] [PDF] A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma Blood, November 15, 2005; 106(10): 3538 - 3545. [Abstract] [Full Text] [PDF] S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24 Clin. Cancer Res., May 1, 2005; 11(9): 3377 - 3384. [Abstract] [Full Text] [PDF] T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes Clin. Cancer Res., November 1, 2004; 10(21): 7402 - 7412. [Abstract] [Full Text] [PDF] F. Grizzi, M. Chiriva-Internati, B. Franceschini, K. Bumm, P. Colombo, M. Ciccarelli, E. Donetti, N. Gagliano, P. L. Hermonat, R. K. Bright, et al. Sperm Protein 17 Is Expressed in Human Somatic Ciliated Epithelia J. Histochem. Cytochem., April 1, 2004; 52(4): 549 - 554. [Abstract] [Full Text] [PDF] M. Chiriva-Internati, F. Grizzi, B. Franceschini, P. L. Hermonat, R. K. Bright, K. Bumm, N. Dioguardi, and W. M. Kast Is sperm protein 17 a useful target for tumor immunotherapy? Blood, September 15, 2003; 102(6): 2308 - 2309. [Full Text] [PDF] B. Zhu, Z. Chen, X. Cheng, Z. Lin, J. Guo, Z. Jia, L. Zou, Z. Wang, Y. Hu, D. Wang, et al. Identification of HLA-A*0201-restricted Cytotoxic T Lymphocyte Epitope from TRAG-3 Antigen Clin. Cancer Res., May 1, 2003; 9(5): 1850 - 1857. [Abstract] [Full Text] [PDF] Z. Wang, Y. Zhang, H. Liu, E. Salati, M. Chiriva-Internati, and S. H. Lim Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies Blood, February 1, 2003; 101(3): 955 - 960. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020